Loading...
XSHG
603882
Market cap1.56bUSD
Jul 10, Last price  
24.62CNY
1D
7.56%
1Q
-7.48%
IPO
124.23%
Name

Guangzhou Kingmed Diagnostics Group Co Ltd

Chart & Performance

D1W1MN
XSHG:603882 chart
P/E
—
P/S
1.89
EPS
—
Div Yield, %
3.84%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
-6.06%
Revenues
6.03b
-16.12%
977,201,9701,356,070,8821,837,857,6922,389,392,2223,221,579,7213,791,717,6834,525,252,8285,269,266,4978,243,763,51611,943,223,62915,476,074,5378,539,627,8997,189,544,7396,030,452,713
Net income
-173m
L-54.56%
44,085,46452,447,03270,807,216140,327,829170,035,213188,505,406233,321,416402,331,1331,509,701,8942,219,640,4502,754,787,050643,382,150-381,241,138-173,243,555
CFO
1.20b
+32.62%
88,437,50075,549,100225,966,983220,388,055292,141,284283,534,715529,623,040661,396,1591,523,107,5662,087,970,5901,947,842,7381,230,820,619906,347,5211,202,009,267
Dividend
Feb 21, 20250.88 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Guangzhou Kingmed Diagnostics Group Co., Ltd. operates as a prominent independent medical laboratory provider. Its extensive service portfolio encompasses a wide array of offerings, such as medical diagnostic information, clinical trial assistance, and comprehensive laboratory services. The company also specializes in food and hygiene testing, health management solutions, and medical cold chain logistics. Additionally, Kingmed engages in scientific research, develops in vitro diagnostics, and utilizes advanced capabilities in healthcare big data, artificial intelligence, and forensic testing. Operating a network of 37 state-of-the-art testing facilities, the company maintains a significant presence across both mainland China and Hong Kong. Established in 2003, its corporate headquarters are situated in Guangzhou, China.
URL
http://www.kingmed.com.cn/
IPO date
Sep 08, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT